CD19 CAR-T cells

Phase 3Cell therapy

CChongqing Precision Biotech Co., Ltd

CD19 CAR-T cells is one of 218 biologic programs targeting Refractory. It is currently in Phase 3.

Indications

Total Trials

Active Trials

217

Competitors

Pipeline

Status by Indication[3][1]

Indication

RefractoryUnknown status

T CellsRecruiting

Cell TherapyNot yet recruiting

Systemic Lupus ErythematosusRecruiting

LymphomaRecruiting

LeukemiaUnknown status

Myasthenia GravisRecruiting

Autoimmune DiseaseNot yet recruiting

Autologous CD19 CAR-TRecruiting

Consolidation TherapyRecruiting

RefractoryPhase 1

Unknown status

T CellsPhase 2

Recruiting

Cell TherapyPhase 1

Not yet recruiting

Systemic Lupus ErythematosusPhase 2

Recruiting

LymphomaPhase 2

Recruiting

LeukemiaPhase 2

Unknown status

Myasthenia GravisPhase 1

Recruiting

Autoimmune DiseasePhase 2

Not yet recruiting

Autologous CD19 CAR-TPhase 3

Recruiting

Consolidation TherapyPhase 2

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

CD19 CAR-T cells

CChongqing Precision Biotech Co., Ltd

Phase 3

3 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Autoimmune Disease

NCT06688799

Phase 2Recruiting

Lymphoma

NCT04661020

Phase 1/2Recruiting

Systemic Lupus Erythematosus

NCT06585514

Q1 2027

Phase 2/3Recruiting

Autologous CD19 CAR-T

NCT03937544

Q3 2027

Phase 1/2Recruiting

Consolidation Therapy

NCT07072494

Q4 2027

Phase 1/2Not yet recruiting

Autoimmune Disease

NCT07161193

Clinical

Trials by Indication[1]

Leukemia6 trials

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04271410·80 enrolled

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Unknown status·TThird Military Medical University·Phase 1·NCT03298828·30 enrolled

CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Unknown status·SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd·Phase 1/2·NCT05381662·10 enrolled

Show 3 more trials

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Unknown status·CChongqing Precision Biotech Co., Ltd·Phase 1/2·NCT04271800·40 enrolled

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

Unknown status·SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd·Phase 1·NCT03064269·10 enrolled

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

Recruiting·—·Phase 1·NCT05333302·10 enrolled

Refractory3 trials

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Unknown status·TTianjin Mycure Medical Technology Co., Ltd·Phase 1·NCT03671460·18 enrolled

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT07233642·18 enrolled

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT07331467·18 enrolled

Lymphoma3 trials

CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma

Unknown status·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·N/A·NCT04237428·20 enrolled

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Recruiting·ZZhejiang University·Phase 2·NCT04661020·36 enrolled

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT03029338·20 enrolled

Systemic Lupus Erythematosus2 trials

Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)

Recruiting·NNational University of Malaysia·Phase 1·NCT06710717·5 enrolled

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Recruiting·—·Phase 1/2·NCT06585514·18 enrolled

B-cell Malignancies2 trials

CD19-CAR-T in B-cell Malignancies Patients

Completed·HHebei Yanda Ludaopei Hospital·Phase 1·NCT03952923·11 enrolled

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Unknown status·SSheba Medical Center·Phase 1/2·NCT02772198·300 enrolled

7 more indications

Autoimmune Disease2 trials

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Not yet recruiting·HHebei Senlang Biotechnology Inc., Ltd.·Phase 1/2·NCT07161193·30 enrolled

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Recruiting·—·Phase 1/2·NCT06688799·18 enrolled

Acute Lymphoblastic Leukemia2 trials

CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Unknown status·SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd·Phase 1/2·NCT03275493·40 enrolled

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT02975687·20 enrolled

T Cells2 trials

CD19-CAR-T Cells in Patients With R/R B-ALL

Unknown status·BBioceltech Therapeutics, Ltd.·Phase 1·NCT03574168·40 enrolled

A Multicenter Study of CAR-T Cells in Primary Ph+All

Recruiting·ZZhejiang University·Phase 2·NCT07252336·50 enrolled

Autologous CD19 CAR-T1 trial

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Recruiting·NNational University of Malaysia·Phase 2/3·NCT03937544·10 enrolled

Myasthenia Gravis1 trial

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis

Recruiting·ZZhejiang University·Phase 1·NCT05828225·9 enrolled

Consolidation Therapy1 trial

CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study

Recruiting·ZZhujiang Hospital·Phase 1/2·NCT07072494·30 enrolled

Cell Therapy1 trial

Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

Not yet recruiting·TThe General Hospital of Western Theater Command·Phase 1·NCT07277504·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 26 trial records for CD19 CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19 CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 3[1]
Company: CChongqing Precision Biotech Co., Ltd

CD19 CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Leukemia6 trials

Refractory3 trials

Lymphoma3 trials

Systemic Lupus Erythematosus2 trials

B-cell Malignancies2 trials

Autoimmune Disease2 trials

Acute Lymphoblastic Leukemia2 trials

T Cells2 trials

Autologous CD19 CAR-T1 trial

Myasthenia Gravis1 trial

Consolidation Therapy1 trial

Cell Therapy1 trial

References

Drug Info

Quick Facts

Related News